BeiGene Company Profile (NASDAQ:BGNE)

About BeiGene (NASDAQ:BGNE)

BeiGene logoBeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290 and BGB-283, as of December 31, 2016. BGB-3111, BGB-290 and BGB-283 are its molecularly targeted agents and is its immuno-oncology agent. BGB-3111 is a potent and highly selective small molecule inhibitor of Bruton's tyrosine kinase (BTK). BGB-283 is a molecule inhibitor of both the monomer and dimer forms of the RAF kinase. BGB-290 is a molecularly targeted, orally available, potent and highly selective inhibitor of the poly ADP ribose polymerase (PARP) family members. BGB-A317 is an investigational humanized monoclonal antibody against the immune checkpoint receptor, PD-1.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:BGNE
  • CUSIP: N/A
  • Web:
  • Market Cap: $2.79492 billion
  • Outstanding Shares: 39,915,000
Average Prices:
  • 50 Day Moving Avg: $70.10
  • 200 Day Moving Avg: $46.56
  • 52 Week Range: $26.43 - $79.89
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -13.65
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $6.42 per share
  • Price / Book: 10.78
  • EBIDTA: ($179,280,000.00)
  • Return on Equity: -65.85%
  • Return on Assets: -49.40%
  • Debt-to-Equity Ratio: 0.57%
  • Current Ratio: 8.38%
  • Quick Ratio: 8.38%
  • Average Volume: 239,406 shs.
  • Beta: -0.82
  • Short Ratio: 14.14

Frequently Asked Questions for BeiGene (NASDAQ:BGNE)

What is BeiGene's stock symbol?

BeiGene trades on the NASDAQ under the ticker symbol "BGNE."

How were BeiGene's earnings last quarter?

BeiGene, Ltd. (NASDAQ:BGNE) released its quarterly earnings data on Wednesday, March, 22nd. The company reported ($1.05) EPS for the quarter, missing the Zacks' consensus estimate of ($0.86) by $0.19. The company had revenue of $1 million for the quarter, compared to analyst estimates of $3.75 million. The firm's quarterly revenue was down 78.6% compared to the same quarter last year. During the same period in the prior year, the company posted ($3.05) EPS. View BeiGene's Earnings History.

Where is BeiGene's stock going? Where will BeiGene's stock price be in 2017?

7 brokers have issued 12-month target prices for BeiGene's stock. Their forecasts range from $58.00 to $86.00. On average, they expect BeiGene's stock price to reach $76.20 in the next twelve months. View Analyst Ratings for BeiGene.

What are analysts saying about BeiGene stock?

Here are some recent quotes from research analysts about BeiGene stock:

  • 1. According to Zacks Investment Research, "BeiGene, Ltd. is a biotechnology company which focused on immuno-oncological therapeutics. The company's clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BeiGene, Ltd. is based in Camana Bay, Cayman Islands. " (8/10/2017)
  • 2. Maxim Group analysts commented, "BeiGene reported 1Q17 results. The company spent $52.5M during the quarter. The increased operating expenses were driven by clinical expansion to pivotal studies. Net loss for the quarter was $50.6M or ($1.27) per share. BeiGene ended the period with $327M of liquidity on the balance sheet. We model rising R&D expenses with clinical advances." (5/11/2017)

Who are some of BeiGene's key competitors?

Who are BeiGene's key executives?

BeiGene's management team includes the folowing people:

  • John V Oyler, Chairman of the Board, Chief Executive Officer, Founder
  • Howard Liang Ph.D., Chief Financial Officer and Chief Strategy Officer
  • Wendy Yan, Senior Vice President, Head of Regulatory Affairs
  • Jason Yang M.D.Suffix is Ph.D., Senior Vice President, Head of Clinical Development
  • Timothy Y. Chen, Director
  • Donald W. Glazer, Director
  • Michael J. Goller, Director
  • Ranjeev Krishana, Director
  • Xiaodong Wang Ph.D., Director

When did BeiGene IPO?

(BGNE) raised $126 million in an initial public offering (IPO) on Wednesday, February 3rd 2016. The company issued 5,500,000 shares at $22.00-$24.00 per share. Goldman Sachs, Morgan Stanley and Cowen and Company acted as the underwriters for the IPO and Baird was co-manager.

Who owns BeiGene stock?

BeiGene's stock is owned by a variety of of retail and institutional investors. Top institutional investors include BAKER BROS. ADVISORS LP (23.60%), FMR LLC (10.04%), Hillhouse Capital Management Ltd. (9.32%), Artal Group S.A. (1.01%), Myriad Asset Management Ltd. (0.97%) and Ariose Capital Management Ltd (0.49%). Company insiders that own BeiGene stock include Bros Advisors Lp Baker, Donald W Glazer, Howard Liang, John Oyler, Ruirong Yuan, Thomas Malley and Xiaodong Wang. View Institutional Ownership Trends for BeiGene.

Who sold BeiGene stock? Who is selling BeiGene stock?

BeiGene's stock was sold by a variety of institutional investors in the last quarter, including Fosun International Ltd, Conning Inc., Candriam Luxembourg S.C.A., Emory University, DAFNA Capital Management LLC, Ariose Capital Management Ltd, TD Asset Management Inc. and Airain ltd. Company insiders that have sold BeiGene stock in the last year include Donald W Glazer, John Oyler and Xiaodong Wang. View Insider Buying and Selling for BeiGene.

Who bought BeiGene stock? Who is buying BeiGene stock?

BeiGene's stock was bought by a variety of institutional investors in the last quarter, including Hillhouse Capital Management Ltd., Alliancebernstein L.P., Employees Retirement System of Texas, Myriad Asset Management Ltd., Artal Group S.A., Alps Advisors Inc., Bank of Montreal Can and NF Trinity Capital Hong Kong Ltd. Company insiders that have bought BeiGene stock in the last two years include Bros Advisors Lp Baker, Howard Liang, Ruirong Yuan and Thomas Malley. View Insider Buying and Selling for BeiGene.

How do I buy BeiGene stock?

Shares of BeiGene can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is BeiGene's stock price today?

One share of BeiGene stock can currently be purchased for approximately $69.21.

MarketBeat Community Rating for BeiGene (NASDAQ BGNE)
Community Ranking:  2.9 out of 5 ( )
Outperform Votes:  105 (Vote Outperform)
Underperform Votes:  75 (Vote Underperform)
Total Votes:  180
MarketBeat's community ratings are surveys of what our community members think about BeiGene and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for BeiGene (NASDAQ:BGNE) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 7 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $76.20 (10.10% upside)

Analysts' Ratings History for BeiGene (NASDAQ:BGNE)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/15/2017Goldman Sachs Group, Inc. (The)Reiterated RatingBuy$43.00 -> $86.00LowView Rating Details
8/7/2017Ladenburg Thalmann Financial ServicesInitiated CoverageBuy -> Buy$81.00HighView Rating Details
7/10/2017Morgan StanleyReiterated RatingOverweight$83.00MediumView Rating Details
7/7/2017Maxim GroupBoost Price TargetBuy$57.00 -> $73.00HighView Rating Details
7/6/2017Robert W. BairdBoost Price TargetOutperform$44.00 -> $58.00HighView Rating Details
6/1/2017William BlairReiterated RatingOutperformLowView Rating Details
10/7/2016Cowen and CompanyReiterated RatingBuyN/AView Rating Details
(Data available from 8/18/2015 forward)


Earnings History for BeiGene (NASDAQ:BGNE)
Earnings by Quarter for BeiGene (NASDAQ:BGNE)
Earnings History by Quarter for BeiGene (NASDAQ BGNE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/22/2017Q4($0.86)($1.05)$3.75 million$1.00 millionViewN/AView Earnings Details
11/10/2016Q316($0.78)($1.08)$1.88 millionViewN/AView Earnings Details
8/10/2016Q2($0.68)($0.73)$2.08 million$0.40 millionViewN/AView Earnings Details
5/11/2016Q1($0.05)($0.97)$0.70 millionViewN/AView Earnings Details
3/30/2016Q4($1.06)($3.05)$1.74 million$4.68 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for BeiGene (NASDAQ:BGNE)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20171($1.20)($1.20)($1.20)
Q3 20171($1.21)($1.21)($1.21)
Q4 20171($1.22)($1.22)($1.22)
(Data provided by Zacks Investment Research)


Dividend History for BeiGene (NASDAQ:BGNE)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for BeiGene (NASDAQ:BGNE)
Insider Ownership Percentage: 24.20%
Institutional Ownership Percentage: 43.69%
Insider Trades by Quarter for BeiGene (NASDAQ:BGNE)
Institutional Ownership by Quarter for BeiGene (NASDAQ:BGNE)
Insider Trades by Quarter for BeiGene (NASDAQ:BGNE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/11/2017Bros. Advisors Lp BakerDirectorBuy176,056$71.00$12,499,976.00View SEC Filing  
7/12/2017Xiaodong WangDirectorSell20,000$72.44$1,448,800.00View SEC Filing  
7/10/2017Donald W GlazerDirectorSell10,810$72.15$779,941.50View SEC Filing  
7/6/2017John OylerCEOSell219,400$64.82$14,221,508.00View SEC Filing  
6/28/2017Xiaodong WangDirectorSell35,000$44.95$1,573,250.00View SEC Filing  
6/23/2017John OylerCEOSell98,500$44.16$4,349,760.00View SEC Filing  
6/2/2017Xiaodong WangDirectorSell5,539$40.00$221,560.00View SEC Filing  
5/4/2017Xiaodong WangDirectorSell14,461$40.80$590,008.80View SEC Filing  
5/1/2017John OylerCEOSell36,149$40.47$1,462,950.03View SEC Filing  
4/5/2017Xiaodong WangDirectorSell11,650$36.83$429,069.50View SEC Filing  
3/24/2017Xiaodong WangDirectorSell38,107$36.96$1,408,434.72View SEC Filing  
3/20/2017John OylerCEOSell31,989$39.39$1,260,046.71View SEC Filing  
3/10/2017Xiaodong WangDirectorSell36,892$39.89$1,471,621.88View SEC Filing  
3/6/2017John OylerCEOSell108,999$40.91$4,459,149.09View SEC Filing  
2/27/2017Xiaodong WangDirectorSell38,351$38.19$1,464,624.69View SEC Filing  
2/21/2017John OylerCEOSell64,963$40.55$2,634,249.65View SEC Filing  
11/23/2016Thomas MalleyDirectorBuy30,000$32.00$960,000.00View SEC Filing  
11/18/2016Bros. Advisors Lp BakerDirectorBuy1,760,495$32.00$56,335,840.00View SEC Filing  
9/28/2016Donald W GlazerDirectorSell41,463$30.66$1,271,255.58View SEC Filing  
9/27/2016Donald W GlazerDirectorSell47,149$29.61$1,396,081.89View SEC Filing  
9/23/2016Donald W GlazerDirectorSell36,443$31.02$1,130,461.86View SEC Filing  
9/21/2016Donald W GlazerDirectorSell67,252$31.42$2,113,057.84View SEC Filing  
2/8/2016Bros. Advisors Lp BakerDirectorBuy1,912,680$24.00$45,904,320.00View SEC Filing  
2/8/2016Howard LiangCFOBuy65,000$1.85$120,250.00View SEC Filing  
2/8/2016Ruirong YuanInsiderBuy130,000$1.85$240,500.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for BeiGene (NASDAQ:BGNE)
Latest Headlines for BeiGene (NASDAQ:BGNE)
DateHeadline logoBeigene Ltd (BGNE) Rating Reiterated by Goldman Sachs Group, Inc. (The) - August 15 at 10:32 PM logoBeiGene, Ltd. (BGNE) Director Bros. Advisors Lp Baker Purchases 176,056 Shares - August 14 at 4:30 PM logoBeiGene (BGNE) Prices of 2.47M Public Offering at $71/ADS - August 12 at 4:11 PM logoBeiGene (BGNE) to Offer and Sell $125M ADSs - August 11 at 3:49 AM logoBeiGene Announces Pricing of $175 Million Public Offering - August 10 at 10:47 PM logoBeiGene, Ltd. (BGNE) Downgraded to "Hold" at Zacks Investment Research - August 10 at 9:06 PM logoBeiGene Reports Second Quarter 2017 Financial Results - August 9 at 4:44 PM logoBeiGene, Ltd. (BGNE) Receives Consensus Recommendation of "Buy" from Brokerages - August 4 at 1:02 PM logoBeiGene, Ltd. (BGNE) to Release Earnings on Tuesday - August 1 at 7:30 AM logoHow WebMD Got Locked Out Of The China Market - July 26 at 5:06 PM logoBeiGene, Ltd. (BGNE) Director Xiaodong Wang Sells 20,000 Shares - July 13 at 7:52 PM logoBeiGene, Ltd. (NASDAQ:BGNE) Director Donald W. Glazer Sells 10,810 Shares - July 12 at 10:50 PM logoComparing TESARO (TSRO) & BeiGene (NASDAQ:BGNE) - July 12 at 12:14 PM logoBeiGene, Ltd. (NASDAQ:BGNE) Raised to Buy at Zacks Investment Research - July 11 at 9:38 PM logoInsider Selling: BeiGene, Ltd. (BGNE) CEO Sells 219,400 Shares of Stock - July 10 at 8:12 PM logo[$$] BeiGene Boosted by Celgene Deal - July 10 at 4:30 PM logoBeiGene, Ltd. (BGNE) Receives Average Rating of "Buy" from Brokerages - July 10 at 1:04 PM logoBeiGene, Ltd. (NASDAQ:BGNE) Receives Overweight Rating from Morgan Stanley - July 10 at 10:32 AM logoBeiGene Ltd. (BGNE) Surged To A New High After Celgene Collaboration - July 8 at 4:09 PM logoBeiGene, Ltd. (BGNE) Price Target Raised to $73.00 at Maxim Group - July 8 at 11:44 AM logoBeiGene Ltd. (BGNE) Has Climbed To A New High On Celgene Deal - July 6 at 4:06 PM logoUS STOCKS-Futures lower ahead of trade, ADP jobs data - July 6 at 4:06 PM logoBeiGene stock surges 12% on Celgene cancer collaboration - July 6 at 4:06 PM logoHow Transformative Is This Licensing Deal for BeiGene? - July 6 at 4:06 PM logoBiotech Movers: Immuno-Oncology Pact With Celgene Sends BeiGene Shares Soaring - July 6 at 4:06 PM logoCelgene signs deal with BeiGene for tumor cancer treatment - July 6 at 4:06 PM logoHere's Why BeiGene Ltd. Rose as Much as 31.4% on Thursday - July 6 at 4:06 PM logoBeiGene, Ltd. (NASDAQ:BGNE) Earns Outperform Rating from Robert W. Baird - July 6 at 9:38 AM logoRecent CELG News - July 6 at 3:12 AM logoCelgene Corporation Enters Into Global Strategic Immuno-Oncology Collaboration with BeiGene to Advance PD-1 Inhibitor Program for Solid Tumor Cancers - July 5 at 10:11 PM logoBeiGene to Host Investor Conference Call on Global Strategic Collaboration with Celgene - July 5 at 10:11 PM logoBeiGene Initiates Pivotal Trial of PD-1 Antibody BGB-A317 in China in Patients with Urothelial Cancer - July 5 at 5:09 PM logoBeiGene (BGNE) Surges: Stock Moves 20.8% Higher - July 5 at 5:09 PM logoThis Biotech Stock Is Surging More Than 20% Today - July 5 at 5:09 PM logoBeiGene, Ltd. (BGNE) PT Set at $52.00 by Maxim Group - July 3 at 5:44 PM logoInsider Selling: BeiGene, Ltd. (BGNE) Director Sells 35,000 Shares of Stock - June 30 at 7:16 PM logo Analysts Anticipate BeiGene, Ltd. (BGNE) Will Post Earnings of -$1.15 Per Share - June 29 at 6:30 PM logoBeiGene Presents Preliminary Phase 1 Data on BGB-A317 in Patients with Hepatocellular Carcinoma at the ESMO 19th World Congress on Gastrointestinal Cancer - June 29 at 5:40 PM logoJohn Oyler Sells 98,500 Shares of BeiGene, Ltd. (BGNE) Stock - June 26 at 10:40 PM logoBeiGene Presents Initial Phase 1 Data on BTK Inhibitor BGB-3111 Combined with Obinutuzumab at the 1 - June 16 at 4:37 PM logoBeiGene Presents Initial Phase 1 Data on BTK Inhibitor BGB-3111 Combined with Obinutuzumab at the 14th International Conference on Malignant Lymphoma and Announces Additional Planned Global Registrational Trials for BGB-3111 - June 16 at 4:37 PM logoBeiGene, Ltd. (BGNE) Given a $52.00 Price Target by Maxim Group Analysts - June 15 at 11:20 PM logoBeiGene (BGNE) Delivers Updated Phase 1 Data on BTK Inhibitor BGB-3111 in Patients with Waldenstrom’s Macroglobulinemia - June 15 at 10:41 PM logoBeiGene Presents Updated Phase 1 Data on BTK Inhibitor BGB-3111 in Patients with Waldenström’s Macroglobulinemia at the 14th International Conference on Malignant Lymphoma - June 15 at 5:41 PM logoBeiGene (BGNE) Announces Updated Phase 1 Data on BTK Inhibitor BGB-3111 in Patients with Chronic Lymphocytic Leukemia & Small Lymphocytic Lymphoma - June 14 at 9:10 PM logoBeiGene Presents Updated Phase 1 Data on BTK Inhibitor BGB-3111 in Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma at the 14th International Conference on Malignant Lymphoma - June 14 at 10:37 AM logoBeiGene to Present Data on BGB-3111 at the 14th International Conference on Malignant Lymphoma and to Host Conference Call - June 7 at 4:10 PM logoHead to Head Review: Calithera Biosciences (CALA) versus Beigene (BGNE) - June 7 at 12:51 PM logoBeigene Ltd (BGNE) Director Xiaodong Wang Sells 5,539 Shares - June 6 at 7:51 PM logo Brokerages Expect Beigene Ltd (BGNE) Will Post Earnings of -$1.15 Per Share - June 5 at 4:08 PM



BeiGene (BGNE) Chart for Friday, August, 18, 2017

This page was last updated on 8/18/2017 by Staff